These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 33823765)

  • 21. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
    Dogra S; Sharma A; Mehta H; Sarkar R
    Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK inhibitor: Introduction.
    Raychaudhuri SP; Raychaudhuri SK
    Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Under Development JAK Inhibitors for Dermatologic Diseases.
    Sideris N; Vakirlis E; Tsentemeidou A; Kourouklidou A; Ioannides D; Sotiriou E
    Mediterr J Rheumatol; 2020 Jun; 31(Suppl 1):137-144. PubMed ID: 32676572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects.
    Klein B; Treudler R; Simon JC
    J Dtsch Dermatol Ges; 2022 Jan; 20(1):19-24. PubMed ID: 34962052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Janus kinase inhibitors : Indications, efficacy, uses, what should be taken into account?].
    von Martial S; Tsianakas A
    Dermatologie (Heidelb); 2024 Mar; 75(3):256-267. PubMed ID: 38100043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
    Svoboda SA; Johnson N; Phillips M
    Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
    Huang IH; Chung WH; Wu PC; Chen CB
    Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of janus kinase inhibitors in the treatment of alopecia areata.
    Triyangkulsri K; Suchonwanit P
    Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
    Lensing M; Jabbari A
    Front Immunol; 2022; 13():955035. PubMed ID: 36110853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
    Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
    Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.
    Zhang Y; Jiang G
    Front Immunol; 2024; 15():1341632. PubMed ID: 38444845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The skin delivery of tofacitinib citrate using transethosomes and hybridized ethosomes/nanostructured lipid carriers for vitiligo therapy: Dermatopharmacokinetics and in vivo assays.
    Hesham H; Rady M; Hathout RM; Abdel-Halim M; Mansour S
    Int J Pharm; 2022 Dec; 629():122387. PubMed ID: 36375683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal.
    Aihie O; Dyer JA
    Mo Med; 2023; 120(1):45-48. PubMed ID: 36860609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.
    Montilla AM; Gómez-García F; Gómez-Arias PJ; Gay-Mimbrera J; Hernández-Parada J; Isla-Tejera B; Ruano J
    Dermatol Ther (Heidelb); 2019 Dec; 9(4):655-683. PubMed ID: 31606872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK/STAT pathway modulation: Does it work in dermatology?
    Gündüz Ö
    Dermatol Ther; 2019 May; 32(3):e12903. PubMed ID: 30964573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
    Kwon S
    Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
    Huang MY; Armstrong AW
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders.
    Kalantari Y; Sadeghi S; Asadi D; Goodarzi A
    Int Immunopharmacol; 2022 Sep; 110():108923. PubMed ID: 35717838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.